生殖医学杂志

参考文献

[1] Practice Committee of the American Society for Reproductive Medicine.Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome:a guideline[J].Fertil Steril,2016,106:1634-1647.

[2] Practice Committee of the American Society for Reproductive Medicine.Prevention of moderate and severe ovarian hyperstimulation syndrome:a guideline[J].Fertil Steril,2024,121:230-245.

[3] Azim AA,Costantini-Ferrando M,Oktay K.Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer:a prospective controlled study[J].J Clin Oncol,2008,26:2630-2635.

[4] 谢瑞，胡琳莉.来曲唑预防卵巢过度刺激综合征的研究进展[J].中华生殖与避孕杂志，2019,39:247-250.

[5] Moore HCF,Unger JM,Phillips KA,et al.Final analysis of the Prevention of Early Menopause Study(POEMS)/SWOG Intergroup S0230[J].J Natl Cancer Inst,2019,111:210-213.

[6] 黄晨阳，孙海翔.妇科恶性肿瘤患者促排卵及胚胎移植方案的选择[J].中国实用妇科与产科杂志，2022,38:614-618.

[7] Cavagna F,Pontes A,Cavagna M,et al.Specific protocols of controlled ovarian stimulation for oocyte cryopreservation in breast cancer patients[J].Curr Oncol,2018,25:e527-532.

[8] Zhang J,Du M,Li Z,et al.Comparison of dydrogesterone and medroxyprogesterone in the progestin-primed ovarian stimulation protocol for patients with poor ovarian response[J].Front Endocrinol(Lausanne),2021,12:708704.

[9] Trabert B,Sherman ME,Kannan N,et al.Progesterone and breast cancer[J].Endocr Rev,2020,41:320-344.

[10] Schirmer DA 3rd,Kulkarni AD,Zhang Y,et al.Ovarian hyperstimulation syndrome after assisted reproductive technologies:trends,predictors,and pregnancy outcomes[J].Fertil Steril,2020,114:567-578.

[11] Di Guardo F,Lello C,Incognito GG,et al.Letrozole and ovarian hyperstimulation syndrome(OHSS):a promising prevention strategy[J].J Clin Med,2023,12:614.

[12] La Marca A,Sighinolfi G,Radi D,et al.Anti-Mullerian hormone(AMH) as a predictive marker in assisted reproductive technology(ART)[J].Hum Reprod Update,2010,16:113-130.

[13] Papanikolaou EG,Pozzobon C,Kolibianakis EM,et al.Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles[J].Fertil Steril,2006,85:112-120.

[14] 王雅琴，杨菁，徐望明，等.取卵后黄体期应用来曲唑降低血中雌激素水平不降低卵巢过度刺激综合征发生率[J].北京大学学报(医学版),2013,45:869-872.

[15] Humaidan P,Kol S,Papanikolaou EG.GnRH agonist for triggering of final oocyte maturation:time for a change of practice?[J].Hum Reprod Update,2011,17:510-524.

[16] Iorio GG,Rovetto MY,Conforti A,et al.Severe ovarian hyperstimulation syndrome in a woman with breast cancer under letrozole triggered with GnRH agonist:a case report and review of the literature[J].Front Reprod Health,2021,3:704153.

[17] Turan V,Bedoschi G,Rodriguez-Wallberg K,et al.Utility of gonadotropin-releasing hormone agonists for fertility preservation:lack of biologic basis and the need to prioritize proven methods[J].J Clin Oncol,2019,37:84-86.

[18] Lambertini M,Moore HCF,Leonard RCF,et al.Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer:a systematic review and meta-analysis of individual patient-level data[J].J Clin Oncol,2018,36:1981-1990.

[19] 陈振烈，曹羽明，张元珍.促性腺激素释放激素激动剂对绝经前化疗女性卵巢功能保护作用的Meta分析[J].生殖医学杂志，2021,30:52-61.

[20] Burstein HJ,Lacchetti C,Anderson H,et al.Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer:American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression[J].J Clin Oncol,2016,34:1689-1701.

[21] Balkenende EME,Dahhan T,Beerendonk CCM,et al.Fertility preservation for women with breast cancer:a multicentre randomized controlled trial on various ovarian stimulation protocols[J].Hum Reprod,2022,37:1786-1794.

[22] Ingold C,Navarro PA,de Oliveira R,et al.Risk of ovarian hyperstimulation syndrome in women with malignancies undergoing treatment with long-acting gonadotropin-releasing hormone agonist after controlled ovarian hyperstimulation for fertility preservation:a systematic review[J].Ther Adv Reprod Health,2023,17:26334941231196545.

[23] Castillo JC,Haahr T,Martínez-Moya M,et al.Gonadotropin-releasing hormone agonist for ovulation trigger - OHSS prevention and use of modified luteal phase support for fresh embryo transfer[J].Ups J Med Sci,2020,125:131-137.

[24] Marin L,Vitagliano A,Capobianco G,et al.Which is the optimal timing for starting chemoprotection with gonadotropin-releasing hormone agonists after oocyte cryopreservation?Reflections on a critical case of ovarian hyperstimulation syndrome[J].J Gynecol Obstet Hum Reprod,2021,50:101815.

[25] Christ J,Herndon CN,Yu B.Severe ovarian hyperstimulation syndrome associated with long-acting GnRH agonist in oncofertility patients[J].J Assist Reprod Genet,2021,38:751-756.

[26] Fatemi HM,Popovic-Todorovic B,Humaidan P,et al.Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone(GnRH) agonist trigger and “freeze-all” approach in GnRH antagonist protocol[J].Fertil Steril,2014,101:1008-1011.

[27] Singh N,Dogra Y,Saini M,et al.Severe early-onset ovarian hyperstimulation syndrome with liver dysfunction in an IVF segmentation cycle[J].BMJ Case Rep,2020,13:e233379.

[28] 中国研究型医院学会血栓与止血专业委员会.D-二聚体实验室检测与临床应用中国专家共识[J].中华医学杂志，2023,103:2743-2756.

[29] Melo VD,Liseth OY,Schmidt WM,et al.Risk of thrombosis in women with cancer undergoing controlled ovarian hyperstimulation for fertility preservation[J].J Assist Reprod Genet,2022,39:2847-2856.

[30] Somigliana E,Peccatori FA,Filippi F,et al.Risk of thrombosis in women with malignancies undergoing ovarian stimulation for fertility preservation[J].Hum Reprod Update,2014,20:944-951.

[31] 曹阳，刘梦瑶，张佳烨，等.卵巢过度刺激综合征并发颅内血栓1例病案报道[J].中华生殖与避孕杂志，2020,40:1022-1025.